Results 111 to 120 of about 45,189 (317)

Spinal and paraspinal inflammatory reactions after epidural steroid injection in a patient taking disease-modifying antirheumatic drugs [PDF]

, 2020
Prachi Patel, Isaac Lam, Benjamin P. Liu, Honorio T. Benzon   +3 more
openalex   +1 more source

Clinical Significance of Gut Microbiota Community Types for Long‐Term Response to Fecal Microbiota Transplantation in Patients With Psoriatic Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Fecal microbiota transplantation (FMT) holds promises as a beneficial supplement to methotrexate in patients with psoriatic arthritis (PsA). We therefore investigated how gut bacterial signatures in patients and donor strain engraftment were associated with long‐term response to FMT.
Panpan Qin, Maja S. Kragsnaes, Dorte K. Holm, Hans Christian Horn, Anna Christine Nilsson, Jens Kjeldsen, Karsten Kristiansen, Torkell Ellingsen   +7 more
wiley   +1 more source

Transition From Psoriasis to Psoriatic Arthritis is Characterized by Distinct Alterations in Peripheral Blood Tc17, Th17, and CD4+ Effector Memory Cells

Arthritis &Rheumatology, EarlyView.
Objective Cellular mechanisms driving transition from psoriasis to psoriatic arthritis have remained largely elusive. Thus, we investigated changes within the peripheral blood T cell compartment associated with the transition phase. Methods In an observational study, 116 patients were examined and categorized into subgroups including psoriasis with at ...
Hanna Graßhoff, Sara Comdühr, Henry Nording, Jacob von Esebeck, Philine Letz, Miriam Prohaczka, Handan Gedik, Henner Zirpel, Elisabeth Spallek, Linh Ha‐Wissel, El‐Baraa Adjailia, Sabrina Arnold, Konstantinos Fourlakis, Sebastian Klapa, Ingo Eitel, Oliver J. Müller, Jens Y. Humrich, Gabriela Riemekasten, Diamant Thaçi, Peter Lamprecht   +19 more
wiley   +1 more source

Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis

Advances in Pharmacological Sciences, 2013
Methotrexate (MTX) is a nonbiological disease-modifying antirheumatic drug that has shown both a good control of clinical disease and a good safety. Usually drug-drug interactions (DDIs) represent the most limiting factor during the clinical management ...
Marinella Patanè, Miriam Ciriaco, Serafina Chimirri, Francesco Ursini, Saverio Naty, Rosa Daniela Grembiale, Luca Gallelli, Giovambattista De Sarro, Emilio Russo   +8 more
doaj   +1 more source

A Review of Ankylosing Spondylitis [PDF]

, 2017
Ankylosing spondylitis (AS) is a systemic autoimmune disorder that induces ankylosis of the spine (fusion of the vertebrae at their various joints) and inflammatory arthritis of peripheral joints among other symptoms.
Owen, Hannah L
core   +1 more source

Effect of Time to Start of Biologic Therapy on Treatment Response in Childhood Arthritis: Results From the UCAN CAN‐DU Cohort

Arthritis &Rheumatology, EarlyView.
Objective To estimate the effect of time from symptom onset to start of biologic treatment on achieving inactive arthritis within six months in a cohort of patients with juvenile idiopathic arthritis (JIA). Methods The international UCAN CAN‐DU study prospectively enrolled patients with JIA across Canada and the Netherlands.
Jelleke B. de Jonge, Sytze de Roock, Dieneke Schonenberg‐Meinema, J. Merlijn van den Berg, Deborah A. Marshall, Sebastiaan J. Vastert, Rae S. M. Yeung, Joost F. Swart, Susanne M. Benseler, on behalf of the UCAN CAN‐DU and UCAN CURE consortia, Adam Huber, Bianca Lang, Chelsea DeCoste, Elizabeth Stringer, Suzanne Ramsey, Alan Rosenberg, Kate Neufeld, Mehul Jariwala, Tristan Kerr, Alexander Mosoiu, Alisa Rachlis, Amy Xu, Arthur Cheng, Brenleigh Jebb, Brian Feldman, Bruno Pereira, Deborah Levy, Dilan Dissanayake, Elizaveta Limenis, Evelyn Rozenblyum, Harper Cheng, Jennifer Ji Young Lee, Lynn Spiegel, Rayfel Schneider, Ronald Laxer, Ruud Verstegen, Shirley Tse, Trang Duong, Andrea Human, David Cabral, Herman Tam, Jaime Guzman, Kim Morishita, Kristin Houghton, Lori Tucker, Mercedes Chan, Ross Petty, Tommy Gerschman, Annet van Royen‐Kerkhof, Berent Prakken, Erika Van Nieuwenhove, Marc Jansen, Nico Wulffraat, Ciarán Duffy, Nadia Luca, Roman Jurencak, Tala El Tal, Claire LeBlanc, Gaëlle Chédeville, Piya Lahiry, Rosie Scuccimarri, Sarah Campillo, Clare Hutchinson, Daniah Basodan, Dax G. Rumsey, Hon Yan Ng, Jeanine McColl, Lillian Lim, Tara McGrath, Danielle Brinkman, Petra Hissink Muller, Elizabeth Legger, Wineke Armbrust, Ellen Schatorje, Esther Hoppenreijs, Elodie Boudes, Gillian Currie, Heinrike Schmeling, Muhammed Dhalla, Nicole Johnson, Paivi Miettunen, Ravneet Sran, Rebeka Stevenson, Erkan Demirkaya, Jonathan Park, Roberta Berard, Giske Biesbroek, Mariken Gruppen, Gordon Soon, Joseph Cafazzo, Liane Heale, Michelle Batthish, Tania Cellucci, Lily Lim, Maarten IJzerman, Marinka Twilt, Marleen Verkaaik, Philomine van Pelt, Sylvia Kamphuis, Michelle Kip, Nickolas Blanchette, Paul Dancey, Regina de Geus   +102 more
wiley   +1 more source

Advances in the Drugs Treatment of Psoriatic Arthritis

Xiehe Yixue Zazhi
Psoriatic arthritis (PsA), an inflammatory articular disease closely associated with psoriasis, is characterized by a wide range of symptoms including skin lesion, peripheral and axial joint involvement, enthesitis, and dactylitis.
LU Chaofan, LENG Xiaomei
doaj   +1 more source

Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab. [PDF]

, 2019
Purpose: The objectives of this study were to evaluate and compare treatment patterns and infusion-related health care resource expenditures for rheumatoid arthritis (RA) patients initiating golimumab for intravenous use (GLM-IV) and infliximab (IFX ...
DeHoratius, Raphael J., Ellis, Lorie A., Kafka, Shelly, Kubacki, Maureen, Malangone-Monaco, Elisabetta, Stetsovsky, Diana, Varker, Helen   +6 more
core   +1 more source

A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA (R)) to the reference product (Humira (R)) in patients with active rheumatoid arthritis [PDF]

, 2017
Background: This study aimed to compare efficacy and safety of test-adalimumab (CinnoRA (R), CinnaGen, Iran) to the innovator product (Humira (R), AbbVie, USA) in adult patients with active rheumatoid arthritis (RA).
Ahmadzadeh, Arman., Ebrahimi, Ali Asghar., Gharibdoost, Farhad., Hajiabbasi, Asghar., Jamshidian, Ahmadreza., Karimzadeh, Hadi., Mahjourian, Najmeh., Mohammadinejad Rashti, Amin., Mousavi, Mohammad., Nazarinia, Mohammad Ali., Rezaieyazdi, Zahra., Sahebari, Maryam., Shakibi, Mohammad Reza., Soroosh, Soosan.G., Soroush, Mohsen., Vojdanian, Mahdi.   +15 more
core   +1 more source

Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient‐Reported Outcomes in a Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Withdrawal Trial

Arthritis &Rheumatology, EarlyView.
Objective Juvenile idiopathic arthritis (JIA) is associated with impaired overall health‐related quality of life (HRQoL). We evaluated the impact of tofacitinib on patient‐reported outcomes (PROs) in patients with JIA. Methods This was a post hoc analysis of a phase 3, randomized, double‐blind, placebo‐controlled withdrawal trial (NCT02592434) in ...
Hermine I. Brunner, Ekaterina Alexeeva, Marcia Bandeira, Ruy Carrasco, Jeffrey Chaitow, Peter Chiraseveenuprapund, Tracy V. Ting, Muferet Erguven, Beth Gottlieb, Sheila Knupp Oliveira, Pooja N. Patel, Seza Ozen, Claudia Saad Magalhaes, Inmaculada Calvo Penadés, David Gruben, Rebecca Germino, Holly B. Posner, Lori Stockert, Alberto Martini, Daniel J. Lovell, Nicolino Ruperto, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG)   +21 more
wiley   +1 more source